Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Participants Requiring Preventive Treatment for Migraine: Results from the Head-to-head TEMPLE Trial (P10-15.009) | Synapse
Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Participants Requiring Preventive Treatment for Migraine: Results from the Head-to-head TEMPLE Trial (P10-15.009)
Puntos clave
To evaluate the tolerability, safety, and efficacy of atogepant compared to topiramate in migraine prevention.
Participants received either atogepant or topiramate for migraine prevention.
Study assessed tolerability and safety outcomes alongside efficacy measures.
Atogepant demonstrated superior tolerability compared to topiramate.
Efficacy outcomes favored atogepant in reducing migraine frequency.
Safety profiles were analyzed, indicating fewer adverse effects with atogepant.
Resumen
Compare the tolerability, safety, and efficacy between atogepant, an oral calcitonin gene-related peptide receptor antagonist, and topiramate in participants requiring preventive migraine treatment.